Prof Katja Weisel speaks to ecancer about the updated interim analysis of the GMMG-Concept trial investigating isatuximab, carfilzomib, lenalidomide and dexamethasone (ISA-KRD) in frontline treatment of high-risk multiple myeloma.

Initially, she explains the rationale and methodology of this trial. Prof Weisel then discusses the results. With a best overall response rate of 100% during quadruplet induction treatment, this trial reported an update of the interim analysis for progression-free survival of the first 50 patients in the CONCEPT trial. These solely high-risk newly diagnosed MM patients had an encouraging PFS rate of 79.6% and 75.5% after 12- and 24-months. The data underlines the high potency of quadruplet treatment with Isa-KRd especially, in patients with HR disease.

Prof Weisel mentions the future impact of the results from this study on the treatment of multiple myeloma.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.